# A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

> **NCT06131450** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 138 (estimated)

## Conditions studied

- Gynecological Malignancies

## Interventions

- **DRUG:** BL-M07D1

## Key facts

- **NCT ID:** NCT06131450
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06131450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06131450, "A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06131450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*